Building Robust Neoantigen Platforms for Clinical Impact

Optimising Translational Testing, Neoantigen Validation, & Novel Therapies to Streamline Clinical Trials & Develop Durable Neoantigen-Targeted Therapies with High Immune Response & Clinical Efficacy

The neoantigen-targeted therapies industry is thawing and coming out of its biotech winter fuelled by Moderna’s recent news showing 49% decrease in disease progression after 5 years. This momentum has reignited confidence across pharma and biotech, accelerating a neoantigen programme and pushing more candidates into the clinic than ever before.

The 9th International Neoantigen Summit returns to Amsterdam to bring together the only dedicated forum for end-end neoantigen development. From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches – this is your only platform dedicated to sharing critical developments in neoantigen therapies.

In a unique position to unite all the key players in the neoantigen industry, including the likes of Nykode Therapeutics, Evaxion, Geneos and more, this summit sits at the heart of the neoantigen industry, making every conversation relevant and every connection intentional.

Attend your only annual checkpoint to access the latest clinical updates, uncover breakthrough innovations and form partnerships that will drive the next wave of neoantigen-targeted therapies forward.

Very relevant presentations, lots of new clinical data. Good opportunities to reconnect with other attendees.

Infinitopes

Infinitopes

I was great to get updates about latest neoantigen therapeutic programmes and to get in touch with colleagues from different countries.

Andarix Pharmaceutical

Andarix Pharmaceutical

Great speaker list and actual topics in the field are addressed. Room for great discussions: after session discussions but also panels and round tables. The audience has a nice size so that it is easy to connect.

Evaxion Biotech

Evaxion Biotech

Explore the Full Event Guide

  • Leverage bioinformatics and AI to overcome major bottlenecks with neoantigen validation to accelerate precision immunotherapy development with Khosen Bio and Transgene
  • Analyse clinical insights from Evaxion’s AI-driven neoantigen personalised cancer vaccine to enhance effectiveness of personalised immunotherapy and improve tumour targeting
  • Explore DNA-encoded neoantigen vaccines and their effectiveness in inducing strong immunity in advanced cancer patients with Nykode Therapeutics
  • Illuminate the dark genome and understand how it can help find targets for affordable, multi-valent immunotherapies with Epitopea
  • Identify the advantage of personalised neoantigen peptide immunotherapy in glioblastoma and how to optimise the pathways to scalability with YGION Biomedical
Placeholder Image

What To Expect

30%

C-level attendance

20+

Leading global speakers

6+

Hours of dedicated networking

5+

Talks featuring clinical data

3

In-depth workshops

1

Unmissable Opportunity

Attending Companies Include

4-768x432

Explore the Agenda

Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.

24-768x432

Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.

15-768x432

Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions